Korro Bio insider plans Rule 144 stock sale

A Korro Bio insider filed a Rule 144 notice for limited sales of vested common stock following recent equity compensation vesting.

Rhea-AI Filing Summary

Korro Bio, Inc. (KRRO) is the issuer for a planned sale of common stock reported under Rule 144 by James (Oliver) O. Dolan. The notice lists a small number of common shares to be sold following restricted stock vesting on June 15, 2026, with prior sales of vested shares already made in June and September 2026.

Key Figures

Shares sold June 16, 2026: 3,383 shares Proceeds June 16, 2026 sale: $36,638.23 Shares sold September 8, 2026: 7,347 shares +2 more

5 metrics

Shares sold June 16, 2026 3,383 shares Common stock sale by James O. Dolan during the past 3 months

Proceeds June 16, 2026 sale $36,638.23 Total consideration for 3,383 common shares sold by James O. Dolan

Shares sold September 8, 2026 7,347 shares Common stock sale by James O. Dolan during the past 3 months

Proceeds September 8, 2026 sale $99,285.52 Total consideration for 7,347 common shares sold by James O. Dolan

Date of restricted stock vesting June 15, 2026 Origin of the shares listed as securities to be sold

Key Terms

Rule 144, Restricted Stock Vesting, attorney-in-fact, Federal Criminal Violations

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 06/15/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Federal Criminal Violations regulatory

"Intentional misstatements or omission of facts constitute Federal Criminal Violations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Korro Bio (KRRO)?

The Form 144 reports that an insider of Korro Bio, Inc. has given notice of intent to sell a limited amount of common stock under Rule 144, mainly related to restricted stock vesting. It is a disclosure of potential sales, not a new issuance by the company.

Who is selling Korro Bio (KRRO) shares in this Form 144?

The notice states that the securities are for the account of James (Oliver) O. Dolan, identified as one and the same person. The filing is signed by Fidelity Brokerage Services LLC as attorney-in-fact for James O. Dolan.

What Korro Bio (KRRO) securities are covered by this Form 144?

The filing covers common stock of Korro Bio, Inc., held through Fidelity Brokerage Services LLC and listed on NASDAQ. The shares to be sold arise from restricted stock vesting on June 15, 2026 and are characterized as compensation.

What past Korro Bio (KRRO) stock sales are disclosed in the last 3 months?

The Form 144 lists two prior sales of common stock by James O. Dolan in the past 3 months: one on June 16, 2026 and another on September 8, 2026, each with specified share counts and total proceeds reported in the notice.

Is Korro Bio (KRRO) issuing new shares in this Form 144 transaction?

No. The Form 144 describes sales by an insider of Korro Bio, Inc. under Rule 144. It concerns the potential resale of existing common shares, primarily from restricted stock vesting, rather than a new issuance of shares by the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:22 PM Accepted by SEC EDGAR 09/09/2026 - 04:21 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002053835
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Korro Bio, Inc.
SEC File Number	001-39062
Address of Issuer	60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MASSACHUSETTS 02141
Phone	617-468-1999
Name of Person for Whose Account the Securities are To Be Sold	Dolan Oliver
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	6	81.62	14725646	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/15/2026	Restricted Stock Vesting	Issuer			6	06/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James O. Dolan 60 First Street 2nd Floor, Suite 250 Cambridge MA 02141	Common	06/16/2026	3383	36638.23
James O. Dolan 60 First Street 2nd Floor, Suite 250 Cambridge MA 02141	Common	09/08/2026	7347	99285.52

144: Remarks and Signature

Remarks	Oliver Dolan and James O. Dolan are one and the same person.
Date of Notice	09/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for James O. Dolan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)